Piper Sandler Maintains Overweight on Kronos Bio, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Kronos Bio (NASDAQ:KRON) but reduced the price target from $7 to $6.

December 19, 2023 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler has maintained an Overweight rating on Kronos Bio, indicating a positive outlook, but has lowered the price target from $7 to $6, suggesting a reduced growth expectation.
While the Overweight rating suggests that Piper Sandler is optimistic about Kronos Bio's future performance, the reduction in the price target may reflect a tempered expectation for the stock's growth potential in the short term. This could lead to mixed reactions in the market, with some investors seeing the lowered target as a sign of caution, while others may focus on the continued positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100